Intratumoral INT230-6 (Cisplatin, Vinblastine, Shao) Alone or with Ipilimumab Prolonged Survival with Favorable Safety in Adults with Refractory Sarcomas (NCT 03058289) November 18, 2022
Safety and survival results from a phase 1/2 trial of intratumoral agent INT230-6 (cisplatin vinblastine) induces immunological cancer cell death alone or with pembrolizumab (PEM) in patients with refractory, metastatic cancers IT-01; Merck KEYNOTE-A10] November 11, 2022
A Phase II Randomized Window of Opportunity Trial Evaluating Cytotoxic and Immunomodulatory effects of Intratumoral INT230-6 (Cisplatin, Vinblastine) in Early-Stage Breast Cancer: the INVINCIBLE Trial November 10, 2022
INT230-6 Demonstrates Activity as Monotherapy and in Combination with Ipilimumab (IPI) Across a Broad Spectrum of Refractory Soft Tissue Sarcomas (STS) [Intensity IT-01; BMS#CA184-592] June 3, 2022
Intratumoral INT230-6 Causes Tumor Necrosis and Promotes a Systemic Immune Response; Results from a Multi-center Phase 1/2 Study of Solid Tumors with and without Pembrolizumab (PEM) [Intensity IT-01; Merck KEYNOTE-A10] June 3, 2022
Intratumoral (IT) INT230-6 Can Cause Tumor Necrosis in vivo: Preliminary Results of a Phase II Randomized Presurgical Window-of-Opportunity Study in Early Breast Cancers (the INVINCIBLE study) – PART I June 3, 2022
Safety and Efficacy of INT230-6, a Potential First-in-Class Intratumoral Therapy, in Monotherapy and in Combination with Pembrolizumab: Results from the IT-01 Study [KEYNOTE-A10] in Subjects with Locally Advanced, Unresectable and Metastatic Breast Cancer December 10, 2021
Survival and Immune Response Data from Intratumoral INT230-6 Alone (IT-01) and with Pembrolizumab [KEYNOTE-A10] in Subjects with Locally Advanced, Unresectable and Metastatic Solid Tumors November 14, 2021
Intratumoral INT230-6 shows a favorable safety profile and early signs of efficacy in advanced soft tissue sarcoma with monotherapy and in combination with Ipilimumab [Intensity IT-01; BMS#CA184-592] November 14, 2021
Safety and Efficacy from a Phase 1/2 Study of Intratumoral INT230-6 Alone or in Combination with Ipilimumab [Intensity# IT-01; BMS# CA184-592] in Adult Subjects with Metastatic Sarcomas (NCT 03058289) November 12, 2021 Presented at the Connective Tissue Oncology Society (CTOS) 2021 Virtual Annual Meeting
